First - Select the target: Better choice of adjuvant treatments for breast cancer patients

Aron Goldhirsch, A. S. Coates, R. D. Gelber, J. H. Glick, B. Thürlimann, H. J. Senn

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

St Gallen Expert Consensus meetings update evidence on treatment of early breast cancer every 2 years and interpret its significance for treatment of individual patients. Such interpretation is controversial. Clinical decisions cannot, however, be postponed, and the harms of failing to tailor treatment must be balanced against those of overinterpretation. Since the ninth meeting in January 2005, an extraordinary year of progress has significantly changed the landscape in breast cancer therapy. The panel in January recommended a fundamental change in selection of adjuvant systemic therapy, giving prime attention to endocrine responsiveness. Primarily, three categories were acknowledged: endocrine responsive in which the primary treatment should be endocrine, endocrine non-responsive in which endocrine therapy should not be used, and an intermediate group for which both endocrine and other therapies should be offered. Secondarily, three risk groups were defined: low, intermediate, and high, slightly modifying the previous classification. In June 2005, three trials, supported in December by a fourth, demonstrated the additional contribution of targeted therapy with trastuzumab in appropriately selected patients. Reports from several trials strengthened the evidence supporting the inclusion of taxanes, though controversy persists concerning their use in endocrine-responsive disease. This commentary midway between St Gallen meetings, therefore, emphasizes how new information influences algorithms for selecting adjuvant therapy in a rapidly changing environment.

Original languageEnglish
Pages (from-to)1772-1776
Number of pages5
JournalAnnals of Oncology
Volume17
Issue number12
DOIs
Publication statusPublished - Dec 2006

Fingerprint

Breast Neoplasms
Therapeutics
Endocrine System Diseases
Taxoids

Keywords

  • Adjuvant therapy
  • Breast cancer
  • Endocrine responsiveness
  • Tailored therapies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Goldhirsch, A., Coates, A. S., Gelber, R. D., Glick, J. H., Thürlimann, B., & Senn, H. J. (2006). First - Select the target: Better choice of adjuvant treatments for breast cancer patients. Annals of Oncology, 17(12), 1772-1776. https://doi.org/10.1093/annonc/mdl398

First - Select the target : Better choice of adjuvant treatments for breast cancer patients. / Goldhirsch, Aron; Coates, A. S.; Gelber, R. D.; Glick, J. H.; Thürlimann, B.; Senn, H. J.

In: Annals of Oncology, Vol. 17, No. 12, 12.2006, p. 1772-1776.

Research output: Contribution to journalArticle

Goldhirsch, A, Coates, AS, Gelber, RD, Glick, JH, Thürlimann, B & Senn, HJ 2006, 'First - Select the target: Better choice of adjuvant treatments for breast cancer patients', Annals of Oncology, vol. 17, no. 12, pp. 1772-1776. https://doi.org/10.1093/annonc/mdl398
Goldhirsch, Aron ; Coates, A. S. ; Gelber, R. D. ; Glick, J. H. ; Thürlimann, B. ; Senn, H. J. / First - Select the target : Better choice of adjuvant treatments for breast cancer patients. In: Annals of Oncology. 2006 ; Vol. 17, No. 12. pp. 1772-1776.
@article{53f6c3e7853441ae9a148d5210ad4184,
title = "First - Select the target: Better choice of adjuvant treatments for breast cancer patients",
abstract = "St Gallen Expert Consensus meetings update evidence on treatment of early breast cancer every 2 years and interpret its significance for treatment of individual patients. Such interpretation is controversial. Clinical decisions cannot, however, be postponed, and the harms of failing to tailor treatment must be balanced against those of overinterpretation. Since the ninth meeting in January 2005, an extraordinary year of progress has significantly changed the landscape in breast cancer therapy. The panel in January recommended a fundamental change in selection of adjuvant systemic therapy, giving prime attention to endocrine responsiveness. Primarily, three categories were acknowledged: endocrine responsive in which the primary treatment should be endocrine, endocrine non-responsive in which endocrine therapy should not be used, and an intermediate group for which both endocrine and other therapies should be offered. Secondarily, three risk groups were defined: low, intermediate, and high, slightly modifying the previous classification. In June 2005, three trials, supported in December by a fourth, demonstrated the additional contribution of targeted therapy with trastuzumab in appropriately selected patients. Reports from several trials strengthened the evidence supporting the inclusion of taxanes, though controversy persists concerning their use in endocrine-responsive disease. This commentary midway between St Gallen meetings, therefore, emphasizes how new information influences algorithms for selecting adjuvant therapy in a rapidly changing environment.",
keywords = "Adjuvant therapy, Breast cancer, Endocrine responsiveness, Tailored therapies",
author = "Aron Goldhirsch and Coates, {A. S.} and Gelber, {R. D.} and Glick, {J. H.} and B. Th{\"u}rlimann and Senn, {H. J.}",
year = "2006",
month = "12",
doi = "10.1093/annonc/mdl398",
language = "English",
volume = "17",
pages = "1772--1776",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "12",

}

TY - JOUR

T1 - First - Select the target

T2 - Better choice of adjuvant treatments for breast cancer patients

AU - Goldhirsch, Aron

AU - Coates, A. S.

AU - Gelber, R. D.

AU - Glick, J. H.

AU - Thürlimann, B.

AU - Senn, H. J.

PY - 2006/12

Y1 - 2006/12

N2 - St Gallen Expert Consensus meetings update evidence on treatment of early breast cancer every 2 years and interpret its significance for treatment of individual patients. Such interpretation is controversial. Clinical decisions cannot, however, be postponed, and the harms of failing to tailor treatment must be balanced against those of overinterpretation. Since the ninth meeting in January 2005, an extraordinary year of progress has significantly changed the landscape in breast cancer therapy. The panel in January recommended a fundamental change in selection of adjuvant systemic therapy, giving prime attention to endocrine responsiveness. Primarily, three categories were acknowledged: endocrine responsive in which the primary treatment should be endocrine, endocrine non-responsive in which endocrine therapy should not be used, and an intermediate group for which both endocrine and other therapies should be offered. Secondarily, three risk groups were defined: low, intermediate, and high, slightly modifying the previous classification. In June 2005, three trials, supported in December by a fourth, demonstrated the additional contribution of targeted therapy with trastuzumab in appropriately selected patients. Reports from several trials strengthened the evidence supporting the inclusion of taxanes, though controversy persists concerning their use in endocrine-responsive disease. This commentary midway between St Gallen meetings, therefore, emphasizes how new information influences algorithms for selecting adjuvant therapy in a rapidly changing environment.

AB - St Gallen Expert Consensus meetings update evidence on treatment of early breast cancer every 2 years and interpret its significance for treatment of individual patients. Such interpretation is controversial. Clinical decisions cannot, however, be postponed, and the harms of failing to tailor treatment must be balanced against those of overinterpretation. Since the ninth meeting in January 2005, an extraordinary year of progress has significantly changed the landscape in breast cancer therapy. The panel in January recommended a fundamental change in selection of adjuvant systemic therapy, giving prime attention to endocrine responsiveness. Primarily, three categories were acknowledged: endocrine responsive in which the primary treatment should be endocrine, endocrine non-responsive in which endocrine therapy should not be used, and an intermediate group for which both endocrine and other therapies should be offered. Secondarily, three risk groups were defined: low, intermediate, and high, slightly modifying the previous classification. In June 2005, three trials, supported in December by a fourth, demonstrated the additional contribution of targeted therapy with trastuzumab in appropriately selected patients. Reports from several trials strengthened the evidence supporting the inclusion of taxanes, though controversy persists concerning their use in endocrine-responsive disease. This commentary midway between St Gallen meetings, therefore, emphasizes how new information influences algorithms for selecting adjuvant therapy in a rapidly changing environment.

KW - Adjuvant therapy

KW - Breast cancer

KW - Endocrine responsiveness

KW - Tailored therapies

UR - http://www.scopus.com/inward/record.url?scp=33845369142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845369142&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdl398

DO - 10.1093/annonc/mdl398

M3 - Article

C2 - 17071934

AN - SCOPUS:33845369142

VL - 17

SP - 1772

EP - 1776

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 12

ER -